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Abstract 
The non disulphide-bridged peptides (NDBPs) of scorpion venoms are attracting increased in-
terest due to their structural heterogeneity and broad spectrum of biological activities. Here, two 
novel peptides, named AcrAP1 and AcrAP2, have been identified in the lyophilised venom of the 
Arabian scorpion, Androctonus crassicauda, through “shotgun” molecular cloning of their bio-
synthetic precursor-encoding cDNAs. The respective mature peptides, predicted from these 
cloned cDNAs, were subsequently isolated from the same venom sample using reverse phase 
HPLC and their identities were confirmed by use of mass spectrometric techniques. Both were 
found to belong to a family of highly-conserved scorpion venom antimicrobial peptides – a finding 
confirmed through the biological investigation of synthetic replicates. Analogues of both peptides 
designed for enhanced cationicity, displayed enhanced potency and spectra of antimicrobial activity 
but, unlike the native peptides, these also displayed potent growth modulation effects on a range of 
human cancer cell lines. Thus natural peptide templates from venom peptidomes can provide the 
basis for rational analogue design to improve both biological potency and spectrum of action. The 
diversity of such templates from such natural sources undoubtedly provides the pharmaceutical 
industry with unique lead compounds for drug discovery. 
Key words: Scorpion; Venom; Molecular Cloning; Antimicrobial; Peptide; analogue design. 
Introduction 
Venoms remain an under-utilised resource for 
drug discovery within the pharmaceutical industry 
despite a track record over many years of providing 
lead compounds for the generation of blockbuster 
drugs such as the ACE inhibitors (captopril) for the 
treatment of hypertension and the first incretin mi-
metic (exenatide) for the treatment of type-2 diabetes 
[1, 2]. Also, the often exquisitely-specific interactions 
between venom proteins/peptides and their cognate 
molecular targets, has been an attribute that has pro-
vided in many instances, a much fuller understanding 
of the functional basis of endogenous regulatory sys-
tems in both man and animals in areas as diverse as 
blood clotting and neuronal excitability [3, 4]. Cur-
rently, the study of venom components with the view 
to the discovery of novel therapeutic lead compounds 
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and novel disease-related molecular targets, is un-
dergoing a renaissance due in part to the failure of 
organic chemistry to fill the fast-emptying pipelines of 
new products from the pharmaceutical industry [3-5]. 
Venom proteomes and peptidomes (venomes) thus 
represent a unique chemical space which can be 
re-evaluated for drug discovery end-points through 
the application of contemporary analytical technolo-
gies [6, 7]. Although venoms from selected species of 
venomous animals have been studied for several 
decades, a systematic approach involving venom 
gland transcriptome sequencing and proteo-
mic/peptidomic inventory of all encoded toxins, has 
not been achieved to date for even a single species. Of 
the total predicted number of venom pro-
teins/peptides occurring in the venoms of all known 
venomous animals that is conservatively, many hun-
dreds of thousands, only a small fraction of a single 
percentage has been isolated and structural-
ly/functionally characterised to date [8, 9]. The po-
tential for drug lead discovery of this unique and 
sizeable library of naturally-selected “smart” mole-
cules, thus remains to be realised. The current study 
focuses on the venom of the buthid scorpion, An-
droctonus crassicaudus (literally, the fat-tailed man 
killer), and more specifically on the group of 
non-disulphide-bridged peptides (NDBPs) that in-
clude the bradykinin-potentiating peptides (BPPs) 
and the antimicrobial peptides (AMPs) [10]. The 
AMPs are widely-distributed in scorpion venoms and 
possess a relatively narrow spectrum of antimicrobial 
activity with little effects on Gram-negative bacteria 
[11]. Here we describe the structural and functional 
characterisation of two similar AMPs initially identi-
fied in the venom of A. crassicauda through “shotgun” 
cloning of their biosynthetic precursor-encoding 
cDNAs from a lyophilised venom-derived cDNA li-
brary. The peptides were C-terminally amidated 
18-mers with the amino acid sequences, 
FLFSLIPH/NAISGLI/LSAFK, and were named in 
accordance with standard nomenclature as AcrAP1 
and AcrAP2, respectively [10]. Synthetic versions of 
both peptides were found to have potent inhibitory 
effects against a reference Gram-positive bacterium 
and a yeast, but to be essentially inactive against a 
reference Gram-negative bacterium, in keeping with 
previous observations for structural homologues [12]. 
Both peptides were inactive against a range of human 
cancer cell lines at concentrations up to and including 
10-4 M. Design, synthesis and biological evaluation of 
cationicity-enhanced analogues of both peptides, re-
sulted in peptides with a more potent and broad 
spectrum antimicrobial activity and which possessed 
growth modulating effects on all human cancer cell 
lines tested. These data are indicative of the potential 
of natural venom peptide templates in the generation 
of analogues with enhanced biological activity and 
spectrum of actions that may be useful leads in the 
development of novel therapeutics.  
Materials and Methods 
Acquisition of scorpion venom 
Authentic lyophilised Androctonus crassicauda 
venom (10 mg) was obtained from Latoxan, Valence, 
France. Donor scorpions were collected in the field 
and identified by experts before relocation to the 
company facility in France. Venom was collected by 
trained individuals using electrical stimulation (15V) 
consistent with obtaining sufficient material and with 
causing a low degree of stress to the animals. Venom 
was obtained by this procedure at regular intervals 
over many months (Latoxan, personal communica-
tion). All procedures requiring the use of live animals 
had been approved by appropriate national licensing 
and local ethics authorities and permits to acquire 
animals from the wild had been secured from appro-
priate national bodies where necessary. 
Molecular cloning of antimicrobial peptide 
biosynthetic precursor-encoding cDNAs from 
a venom-derived cDNA library 
A 5 mg sample of Androctonus crassicauda venom 
was first dissolved in 1ml of cell lysis/mRNA stabili-
sation buffer (Dynal Biotech, UK). Polyadenylated 
mRNA was isolated by means of magnetic oligo-dT 
beads as described by the manufacturer (Dynal Bio-
tech, UK) and subjected to 3′-RACE procedures to 
obtain full-length antimicrobial peptide biosynthetic 
precursor nucleic acid sequence data using a 
SMART-RACE kit (Clontech UK) following manu-
facturer’s instructions. The 3′-RACE reactions em-
ployed an NUP primer (supplied with the kit) and a 
sense primer (S1; 5′-GATGGAAATAAAGTATCTTCT
TACCGT-3′) that was designed to a highly- conserved 
domain of the signal peptide region of previous-
ly-characterised antimicrobial peptide precursor 
cDNAs from closely-related Androctonus scorpion 
species [12]. The PCR cycling procedure was as fol-
lows—initial denaturation step: 60 s at 94 °C; 35 cy-
cles: denaturation 30 s at 94 °C, primer annealing for 
30 s at 62 °C; extension for 180 s at 72°C. Resultant 
PCR products were gel-purified, cloned using a 
pGEM-T vector system (Promega Corporation) and 
sequenced using an ABI 3100 automated capillary 
sequencer. 
Isolation and structural characterisation of 
antimicrobial peptides from lyophilised venom 
A second 5 mg sample of lyophilised Androcto-
nus crassicauda venom was dissolved in 0.5ml of tri-
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fluoroacetic acid (TFA)/water (0.05/99.95; v/v) and 
clarified by centrifugation (1100 x g; 5 min). The su-
pernatant was decanted and subjected to re-
verse-phase HPLC fractionation using a Waters HPLC 
system fitted with an analytical column (Phenomenex 
C-5; 250 mm×4.6 mm). This was eluted with a linear 
gradient formed from TFA/water (0.05/99.95; v/v) to 
TFA/water/acetonitrile (0.05/19.95/80.00; v/v/v) in 
240 min at a flow rate of 1 ml/min. The column ef-
fluent was continuously monitored at λ214 nm and 
fractions (1 ml) were automatically collected at minute 
intervals. The computed molecular masses of the 
novel mature peptides, predicted from open-reading 
frames within the novel cloned cDNAs, were used to 
interrogate a mass spectral library of venom peptides 
derived from sequential analysis of each reverse 
phase HPLC fraction using matrix-assisted laser de-
sorption/ionisation, time-of-flight mass spectrometry 
(MALDI-TOF MS) on a linear time-of-flight Voyager 
DE mass spectrometer (Perseptive Biosystems, MA, 
USA) in positive detection mode using 
α-cyano-4-hydroxycinnamic acid as the matrix. In-
ternal mass calibration of the instrument was achieved 
using standard peptides that provided a determined 
accuracy of ±0.1%. The peptides with masses coinci-
dent with the novel putative cDNA-encoded peptides 
were subjected to primary structural analysis by 
means of MS/MS fragmentation sequencing using an 
LCQ-Fleet electrospray ion-trap mass spectrometer 
(Thermo Fisher Scientific, CA, USA).  
Prediction of putative AMP secondary 
structures and physico-chemical properties 
Putative peptide secondary structures were pre-
dicted using GOR secondary structure prediction 
software (http://distill.ucd.ie/distill/). Additional 
physico-chemical properties, including hydrophobi-
city, hydrophobic moment, net charge at neutral pH 
and helical wheel plots, were determined using the 
Heliquest server menu (http://heliquest.ipmc. 
cnrs.fr/cgi-bin/ComputParamsV2.py) [13].  
Peptide synthesis  
Each natural antimicrobial peptide and their re-
spective cationicity-enhanced analogues, were sepa-
rately synthesised by solid phase methodology using 
Rink amide resin and standard Fmoc chemistry, by 
means of an automated PS3 peptide synthesiser (Pro-
tein Technologies, USA), followed by standardised 
deprotection and cleavage from resin. Each synthetic 
peptide was analysed by reverse phase HPLC and 
MALDI-TOF mass spectrometry to establish both de-
gree of purity and authenticity of structure.  
Antimicrobial minimal inhibitory 
concentration (MIC) and minimum 
bactericidal (MBC) assays 
The antimicrobial activity of each synthetic pep-
tide was assessed by determining their minimal in-
hibitory concentrations (MICs) against reference 
strains of a Gram-positive bacterium, Staphylococcus 
aureus (NCTC 10788), a Gram-negative bacterium, 
Escherichia coli (NCTC 10418), and a yeast, Candida 
albicans (NCPF 1467). The reference strains of micro-
organisms were initially incubated in Mueller-Hinton 
Broth (MHB) for 16-20 h. Upon achieving their re-
spective logarithmic growth phases, as measured by 
the optical density (OD) of cultures at 550 nm, each 
was diluted to 1 × 106 colony-forming units (cfu)/ ml 
(bacteria) or to 5 × 105 cfu/ ml (yeast). Samples of each 
were then added to 96-well microtitre plates to which 
the peptides to be tested were added to achieve final 
on-plate concentrations of 1 – 250 µM. After 24 h in-
cubation, the OD of each well was measured at 550 
nm using a Synergy HT plate reader (BioTek, USA), 
and the data were analysed using GraphPad Prism 5 
software. The MIC was defined as the minimum 
concentration of peptide that produced an OD similar 
to that of the negative control (medium minus micro-
organisms). After this, 10μl of the medium from each 
well was inoculated onto a Mueller-Hinton agar 
(MHA) plate and incubated for 24h for measurement 
of minimum bactericidal concentrations (MBCs) 
which were defined as the concentration of peptide 
from the MIC experiments from which no colonies 
could be grown.  
Haemolysis assay 
Defibrinated horse blood (TCS Biosciences Ltd, 
UK) was used to produce a 2% (v/v) suspension of 
red blood cells in sodium phosphate-buffered saline 
(PBS) by repeated suspensions and centrifugations 
until clear supernatants were achieved. Peptide solu-
tions were prepared to achieve final concentrations in 
the test tubes of 1 – 250 µM. Samples (200 μl) of red 
blood cell suspensions were incubated with peptides 
at 37oC for 60 min. The degree of lysis of red blood 
cells was assessed by haemoglobin release measured 
by optical density changes of supernatants at λ550 nm 
using an ELISA plate reader (BioTek EL808). Negative 
controls employed consisted of a 2% (v/v) red cell 
suspension and PBS in equal volumes and positive 
controls consisted of a 2% (v/v) red cell suspension 
and an equal volume of PBS containing 2% (v/v) of 
the non-ionic detergent, Triton X-100 (Sig-
ma–Aldrich).  
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Culture and maintenance of human cancer cell 
lines 
The human prostate carcinoma cell line, PC-3, 
and the human lung adenocarcinoma cell line, 
NCI-H460, were cultured using RPMI-1640 culture 
medium (Invitrogen). Before culturing cells, this me-
dium was supplemented with 10% (v/v) foetal bovine 
serum (FBS) (Sigma) and 0.1% (w/v) gentamicin 
(Sigma) and the cells were seeded into 150 cm2 culture 
flasks (Nunc, UK). The human breast carcinoma cell 
line, MDA-MB-435s, and the tumourigenic mammary 
gland cell line, MCF-7, were cultured using a Dul-
becco’s Modified Eagle’s Medium (DMEM) (Sigma), 
which was supplemented with 10% FBS and 0.1% 
gentamicin. The cells were seeded into 150 cm2 culture 
flasks. 
 
Assessment of growth modulating effects of 
synthetic natural peptides and their analogues 
on human cancer cells using the MTT cell 
viability assay 
Yellow-coloured MTT (3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide) is reduced by 
the mitochondria of living cells to form a pur-
ple-coloured (formazan) crystalline derivative. These 
crystals can be solubilised by the addition of dimethyl 
sulphoxide (DMSO) and their concentration deter-
mined spectrophotometrically, as detailed below. 
The protocol employed has been described in 
detail previously [14]. Briefly, each cell line was 
seeded onto 96-well plates at a density of 5 × 103 cells 
per well. After this, cells were treated with a range of 
peptide concentrations (10-9 – 10-4M) or with se-
rum-free medium alone (n=8 for each) and were in-
cubated for 24 h at 37oC. This was repeated 
in triplicate, randomizing lines in which 
tests and controls were placed. Following 
this, 10 μl of a 5 mg/ml MTT solution was 
added to each well and the plates were in-
cubated for an additional 4 h. The growth 
medium was then removed using a 1 ml 
syringe fitted with a 21-guage needle and 
100 μl of DMSO were added to each well and 
mixed vigorously to dissolve the formazan 
crystals that had developed. The absorbance 
was measured using an EL808™ Absorbance 
Microplate Reader (Biolise BioTek, USA) at 
λ550 nm and the statistical analyses were 
performed using Student's t-test through 
GraphPad prism software for Windows. The 
results were considered to be statistically 
significant if the p value was <0.05.  
Results 
Molecular cloning of venom precursor 
cDNAs encoding A crassicauda 
antimicrobial peptides (AcrAPs) 
 From the A. crassicauda venom-derived 
cDNA library, two novel putative antimi-
crobial peptide precursor-encoding cDNAs 
were consistently cloned (Figure 1A and B). 
The translated open-reading frames of both 
transcripts displayed a high degree of pri-
mary structural identity and each contained 
74 amino acid residues. Alignments of 
open-reading frame nucleotide (Figure 2A) 
and amino acid sequences (Figure 2B), using 
the AlignX programme of the Vector NTI 
bioinformatics suite (Informax), revealed 
that putative antimicrobial pep-
tide-encoding regions were located in iden-
 
Figure 1. Nucleotide and translated open-reading frame amino acid sequences of 
cloned cDNAs encoding the biosynthetic precursors of AcrAP1 (A) and AcrAP2 (B). 
Putative signal peptides are double-underlined, mature peptides are single-underlined 
and stop codons are indicated by asterisks. 
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tical positions within respective precursors. Both 
AcrAP-encoding precursors exhibited high degrees of 
both nucleotide and primary structural similarity 
with heterogeneity predominantly localised to their 
C-terminal regions. AcrAP precursor structures were 
constituted by a signal peptide domain, a single copy 
of an AcrAP-encoding domain and a C-terminal ex-
tension peptide domain. Both AcrAP sequences were 
flanked C-terminally by glycyl residues that are posi-
tioned to act as amide donors to the C-terminal resi-
due of the mature peptides. 
 Identification of AcrAP1 and AcrAP2 in 
reverse phase HPLC fractions of venom and 
their primary structural confirmation 
A single fraction (#168) containing peptides with 
molecular masses coincident with those of both novel 
putative antimicrobial peptides (AcrAP1 and AcrAP2) 
predicted from respective cloned cDNAs, was re-
solved following reverse phase HPLC fractionation of 
lyophilised venom (Figure 3A and B). Subsequent 
MS/MS fragmentation sequencing of doubly-charged 
ions arising from both peptides, identified in full scan 
MS spectra and analysed through ion trapping in the 
LCQ electrospray mass spectrometer, confirmed their 
predicted primary structures (Figure 4A and B).  
Prediction of putative AMP secondary 
structures and physico-chemical properties 
Helical wheel plots of both AcrAP1 and AcrAP2 
were constructed and are illustrated in Figure 5A and 
B. These plots revealed and amphipathic character in 
both peptides with the hydrophobic amino acid resi-
due (I, F, L, A) side-chains essentially occurring on 
one face of the molecules and the hydrophilic amino 
acid residue (K, S, H, N) side-chains, occurring on the 
other. In view of this arrangement, it was decided to 
synthesise analogues of each peptide in which the 
hydrophilic amino acid residues were substituted 
with lysyl (K) residues to construct a cationic amphi-
pathic peptide in which the hydrophobic amino acid 
residue side-chains occupied one face of the molecule 
while the positively-charged (cationic) amino acid 
residue side-chains occupied the other (Figure 5C and 
D). Table 1 summarises a sample of the 
relevant physico-chemical properties of 
natural AcrAP1 and AcrAP2 and their re-
spective cationicity-enhanced analogues, 
AcrAP1a and AcrAP2a. The primary 
structures and molecular masses of each of 
the 4 peptides used in this study are shown 
in Figure 6A and the closest structural 
homologue to the AcrAPs, AamAP1 (An-
droctonus amoreuxi antimicrobial peptide 1 
[12]), identified through NCBI-BLASTp 
analysis, is aligned with these in Figure 6B.  
Minimal inhibitory concentrations 
(MIC), minimum bactericidal 
concentrations (MBC) and 
haemolytic activity of the synthetic 
natural peptides and their 
cationicity-enhanced analogues 
These data are summarised in Table 2. 
The replicates of the natural peptides, 
AcrAP1 and AcrAP2, displayed identical 
potencies against all three reference mi-
croorganisms in both MIC and MBC assays 
(MIC S. aureus 8 µM, E. coli >250 µM, C. 
albicans 16 µM; MBC S. aureus 32 µM, E. coli 
–not tested, C. albicans 64 µM). The cation-
icity-enhanced analogues of both peptides 
exhibited a significant increase in potency 
and spectrum of action and their respective 
MICs and MBCs were likewise identical 
with one exception (MBC s of AcrAP1a and 
AcrAP2a for C. albicans were 4 µM and 
 
Figure 2. Alignment of nucleotide sequences of cloned cDNAs encoding the biosynthetic 
precursors of AcrAP1 and AcrAP2 (A). Sites of nucleotide sequence differences are 
shown in bold typeface and are underlined. Alignment of translated open-reading frame 
amino acid sequences of cloned cDNAs encoding the biosynthetic precursors of AcrAP1 
and AcrAP2 (B). Respective mature peptide sequences are shown in bold typeface and 
sites of amino acid substitutions are underlined.  
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8µM, respectively). MICs for S. aureus were 4 µM, E. 
coli 8 µM and C. albicans 4 µM, while MBCs were 32 
µM for both S. aureus and E. coli. The concentrations of 
peptides effecting 100% lysis of horse red blood cells 
were 64 µM (AcrAP1 and AcrAP2) and 32 µM 
(AcrAP1a and AcrAP2a).  
 
 
Table 1. Physico-chemical characteristics of the natural A. cras-
sicauda antimicrobial peptides, AcrAP1 and AcrAP2, and their 
cationicity/amphipathicity enhanced analogues, AcrAP1a and 
AcrAP2a. C = random coil and H = α-helix. 
Peptides  Secondary structure α-helix 
(%) 
Hy-
dropho
bicity 
(H) 
Hydro-
phobic 
moment 
(μH) 
Net 
charge 
AcrAP1 FLFSLIPHAISGLISAFK 
CHHHHHHHHHHHHHHHCC  
83.33 0.902 0.437 +2 
AcrAP2 FLFSLIPNAISGLLSAFK 
CHHHHHHHHHHHHHHHCC 
83.33 0.856 0.474 +2 
AcrAP1a FLFKLIPKAIKGLIKAFK 
CHHHHHHHHHHHHHHHHC 
88.89 0.681 0.640 +6 
AcrAP2a FLFKLIPKAIKGLLKAFK 
CHHHHHHHHHHHHHHHHC  
88.89 0.676 0.639 +6 
 
 
Table 2. Mean inhibitory concentrations (MICs) and and mini-
mum bactericidal concentrations (MBCs) of AcrAP1, AcrAP2, 
AcrAP1a and AcrAP2a against the test micro-organisms employed 
and their concentrations effecting 100% lysis of horse erythro-
cytes.  
Peptides MIC (µM)  MBC (µM) 100% Haemolysis (µM) 
S. 
aureus 
E. 
coli 
C. albi-
cans 
S. 
aureus 
E. 
coli 
C. Horse red cells 
albicans  
AcrAP1 8 >250 16 32 NT  64 64 
AcrAP2 8 >250 16 32 NT  64 64 
AcrAP1a 4 8 4 32 32  4 32 
AcrAP2a 4 8 4 32 32  8 32 
 
 
 
Figure 3. Region of reverse phase HPLC chromatogram of Androctonus crassicauda venom with an arrow indicating the retention time/elution position of 
absorbance peak (fraction #168) containing both AcrAP1 and AcrAP2 (A). MALDI-TOF mass spectrum of a sample of fraction #168 indicating major ions 
(M+H)+ corresponding in m/z values to AcrAP1 (1961.76) and AcrAP2 (1937.39) (B). 
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Figure 4. Predicted b- and y-ion series (singly-, doubly- and triply-charged) arising from MS/MS fragmentation of AcrAP1 (A) and AcrAP2 (B). Observed 
ions are indicated in bold typeface and are underlined. 
 
Assessment of growth modulating effects of 
synthetic natural peptides and their analogues 
on human cancer cells  
Both synthetic natural peptides, AcrAP1 and 
AcrAP2, were found to be ineffective in modulating 
the growth of any of the four human cancer cell lines 
tested at the concentrations employed (10-4 – 10-9 M) 
(data not shown). In contrast, both cationici-
ty-enhanced analogues, AcrAP1a and AcrAP2a, dis-
played potent but subtle differences in their effects on 
all four cancer cell lines tested (Figure 7A –D). Inhibi-
tion of proliferation of all cell lines was observed with 
both analogue peptides at concentrations above 10-6 
M, with IC50 values ranging between 2.068 x 10-6 M 
and 3.603 x 10-6 M (p<0.001) (Figure 7 A-D). An intri-
guing observation was that of a significant promotion 
of growth of both H460 and PC-3 cells with AcrAP1a 
at concentrations below 10-6 M (Figure 7 A and D). At 
concentrations of 10-7 M (p<0.05), 10-8 M (p<0.01) and 
10-9 M (p<0.001), AcrAP1a caused proliferation of 
H460 cells (Figure 7A) and at concentrations of 10-8 M 
(p<0.001) and 10-9 M (p<0.001), caused proliferation of 
PC-3 cells (Figure 7D). This effect was not observed 
for AcrAP2a on any of the cancer cell lines tested. At 
the concentration of AcrAP1a (10-9 M) producing the 
most significant growth promotion effects on both 
H460 and PC-3 cancer cell lines (p>0.001), the peptide 
produced no observable haemolysis. 
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Figure 5. Helical wheel plots of AcrAP1 (A), AcrAP2 (B), AcrAP1a (C) 
and AcrAP2a (D). Sites of amino acid substitutions are indicated in each 
peptide (underlined).  
 
Figure 6. Comparative alignment of the natural AMPs, AcrAP1 and 
AcrAP2, with their cationicity-enhanced analogues, AcrAP1a and AcrAP2a 
(A). Alignment of AcrAP1 and AcrAP2 with the most similar AMP found in 
the NCBI database, AamAP1 (Androctonus amoreuxi) (B). Sites of amino 
acid differences are underlined in each case. 
 
Discussion 
Molecular products from natural sources have 
long been the mainstay of drug lead discovery and, 
while originally these were largely constituted by 
secondary metabolites from plants and microbes, 
currently there is a greater emphasis on more complex 
natural molecules, most notably proteins and pep-
tides [3-5, 15, 16]. 
Animal venoms are a unique and largely un-
tapped resource for this procedure and contain an 
abundance of proteins and peptides whose often 
highly-targeted functions have been subjected to nat-
ural selective processes for aeons [3-5, 15, 16]. While 
usage of the standard twenty or so proteogenic amino 
acids can provide the basis for a large number of 
primary structural permutations in oligopeptides and 
proteins, the addition of one or more of the many 
known post-translational chemical modifications to 
peptide chains, can elegantly provide several orders 
of higher molecular complexity and diversity [8, 9, 17, 
18]. Thus while the proteins/peptides of animal 
venoms can in some instances provide templates for 
drug design, in a broader sense, they can be used by 
pharmacologists to reveal the complexity of regula-
tion of known disease-associated targets or to identify 
novel targets [1-5, 15, 16]. Differential functionality 
and receptor targeting can often be provided through 
just single site-specific amino acid substitutions or 
post-translational modifications and most of the 
known modifications have been found within the 
proteomes/peptidomes of animal venoms [8, 9]. Ad-
ditionally, natural templates can be rationally modi-
fied to design analogues with enhanced properties for 
discrete biological end-points and that was the strat-
egy adopted in the present study. 
 Synthetic replicates of both AcrAP1 and AcrAP2 
were found to possess relatively potent antimicrobial 
activity against a reference Gram-positive bacterium 
(MIC 8 µM) and a yeast (MIC 16 µm) but exhibited no 
activity against a reference Gram-negative bacterium 
at concentrations up to and including, 250 µM. These 
values would be similar to those reported for other 
members of this AMP family from the venoms of 
other scorpions [10, 12]. 
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Figure 7. Effects of the cationicity-enhanced analogues, AcrAP1a and AcrAP2a, on the proliferation of four human cancer cell lines, H460 (A), MB435s (B), 
MCF-7 (C) and PC3 (D). *p<0.05, **p<0.01, ***p<0.001. Each panel represents the mean and standard error of 24 replicates. 
 
 As many AMPs exhibit anti-proliferative actions 
on cultured cancer cell lines in vitro [19], the synthetic 
replicates of both natural peptides were incubated at a 
range of concentrations with four different human 
cancer cell lines but with little if any observed effects. 
Thus the natural AMPs described here possessed a 
relatively narrow spectrum of action. However, while 
the natural templates may have relatively low poten-
cies and spectra of actions with respect to both pro-
karyotic and eukaryotic cell proliferation, they nev-
ertheless provide templates or lead structures for the 
rational design of analogues with potential enhanced 
properties for these end-points [20]. Helical wheel 
modelling of AcrAP1 and AcrAP2 revealed their 
amphipathic nature with one hydrophobic face and 
an opposite hydrophilic face (Figure 6A and B). Ana-
logues of both were synthesised, in which the residues 
whose side-chains constituted the neutral hydrophilic 
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face, were substituted with lysyl (K) residues, thus 
producing classical cationic amphipathic peptide 
constructs (Figure 6C and D). This manipulation 
produced peptides with enhanced antimicrobial po-
tencies (MICs of 4 µM) against both the reference 
Gram-positive bacterium and the yeast, and a broad-
ening of spectrum of action to the reference 
Gram-negative bacterium (MIC 8 µM). The MBC 
against the yeast was particularly potent between 4 
and 8 µM. Perhaps the most startling biological effect 
observed was the manifestation of growth modulat-
ing effects on each of the four human cancer cell lines 
employed that were not observed for the synthetic 
replicates of the natural peptides. The cationici-
ty-enhanced analogues were isobaric and differed by 
just a single amino acid residue – I/L at position 14. 
Despite this small structural difference, both peptide 
analogues were different in their proliferative effects 
on the four cancer cell lines. Both peptides exhibited 
highly-significant (p<0.001) anti-proliferative effects 
on all four cancer cell lines tested at concentrations of 
10-4 and 10-5 M. These anti-proliferative effects are 
probably due to lysis of cells as has been reported for 
several other amphibian skin AMPs and also AMPs 
from other sources [19-22]. However, an unexpected 
observation with the analogue, AcrAP1a, was a selec-
tive and highly-significant increase in proliferation of 
both H460 and PC3 cells at concentrations a low as 
10-9 M (p<0.001). While the cause of this unusual effect 
is unknown and undoubtedly warrants further 
in-depth investigation, there could be several expla-
nations, albeit speculative at present. Perhaps the 
most compelling relates to the observations that some 
AMPs from amphibian skin secretions, at concentra-
tions several orders of magnitude below those that 
produce cytolysis, are capable of inducing insulin 
release from insulinoma-derived cell lines [23] and 
cytokine release from macrophages [24]. It is pro-
posed that binding of these AMPs at low, 
non-cytolytic concentrations to secretory cell mem-
branes, can cause localised perturbation effects, such 
as depolarisation, that can lead to stimulation of re-
lease of endogenous secretory vesicles. Some cancer 
cells are known to produce autocrine/paracrine 
growth factors [25] and it is possible that the cancer 
cell lines, H460 and PC3, are among these. If so, then 
increased secretion of such growth factors could ex-
plain the highly-significant increases in proliferation 
observed here. Recent reports have suggested that 
some established and widely-used anticancer drugs, 
such as doxorubicin, while manifesting obvious an-
ti-cancer effects, can promote the growth of cells in the 
cancer which exhibit cancer stem cell phenotypes and 
these are often drug-resistant and metastatic [26]. This 
effect can in part be explained by activation of the 
TGFβ signalling pathway. This cytokine acts in a 
paracrine fashion and plays a fundamental role in cell 
proliferation and differentiation [27]. The study of this 
cytokine in H460 and PC3 cells is thus warranted in 
light of these facts. 
 In summary, the isolation of two novel AMPs 
from the venom of the scorpion, Androctonus crassi-
cauda, is described. Following cloning of biosynthetic 
precursor-encoding cDNAs and identifica-
tion/structural characterisation of both mature pep-
tides in venom, each was chemically-synthesised 
along with respective cationicity-enhanced analogues. 
Biological testing of all four peptides, revealed that 
the synthetic natural peptides had a moderately po-
tent but narrow spectrum of antimicrobial activity. In 
contrast, the cationicity-enhanced analogue of each 
exhibited a broader spectrum of activity with an as-
sociated increase in potency. Modulation of prolifera-
tive activity of several human cancer cell lines was not 
observed for the synthetic natural peptides but was 
for their respective analogues. While both analogues 
exhibited highly-significant anti-proliferative cyto-
toxic effects on all cell lines tested at micromolar (10-6 
M) concentrations, the analogue AcrAP1a caused a 
highly-significant proliferative effect on two cell lines, 
H460 and PC3, at nanomolar (10-9 M) concentrations. 
This contradictory concentration-dependent effect 
would thus constitute a serious problem in their fur-
ther development as anti-cancer agents. Nevertheless, 
these data demonstrate that the natural peptide tem-
plates found in animal venoms, while possessing in-
trinsic biologically-active properties, can be chemi-
cally-manipulated through analogue design, to en-
hance such or indeed to produce novel actions. Both 
facilitations readily illustrate the considerable poten-
tial of these natural peptide templates in drug design 
and development. 
Data deposition footnote 
The nucleotide sequences of AcrAP1 and 
AcrAP2, from the venom of the scorpion, Androctonus 
crassicauda, have been deposited in the EMBL Nucle-
otide Sequence Database under the accession codes, 
HG939518 and HG939519. 
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